ly 293111 has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barile-Thiem, B; Brail, L; Budman, DR; Cleverly, A; de Alwis, DP; O'Reilly, E; Schwartz, GK; Vinciguerra, V; Weitzman, A | 1 |
| Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A | 1 |
2 trial(s) available for ly 293111 and Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzoates; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptors, Leukotriene B4; Safety | 2005 |
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Ontario; Time Factors; Treatment Outcome | 2007 |